Skip to Content


Active Substance: sitaxentan sodium
Common Name: sitaxentan sodium
ATC Code: C02KX03
Marketing Authorisation Holder: Pfizer Ltd.
Active Substance: sitaxentan sodium
Status: Withdrawn
Authorisation Date: 2006-08-10
Therapeutic Area: Hypertension, Pulmonary
Pharmacotherapeutic Group: Antihypertensives

Therapeutic Indication

Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

The marketing authorisation for Thelin has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.